Prime Medicine, Inc. (NASDAQ: PRME) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
3.12
-0.02-0.64%
News
Down 0.6% — Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout (Yahoo).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.10 | Insider Own | 39.72% | Shs Outstand | 180.62M | Perf Week | -0.32% |
| Market Cap | 563.53M | Forward P/E | - | EPS next Y | -0.92 | Insider Trans | 0.00% | Shs Float | 59.17M | Perf Month | -11.86% |
| Enterprise Value | 628.55M | PEG | - | EPS next Q | -0.23 | Inst Own | - | Short Float | 62.13% | Perf Quarter | -3.41% |
| Income | -191.49M | P/S | 138.36 | EPS this Y | 12.19% | Inst Trans | - | Short Ratio | 11.11 | Perf Half Y | -15.22% |
| Sales | 4.07M | P/B | 13.89 | EPS next Y | 4.83% | ROA | -75.45% | Short Interest | 36.76M | Perf YTD | -10.09% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -188.27% | 52W High | 6.94 -55.04% | Perf Year | -32.90% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -86.83% | 52W Low | 2.67 16.85% | Perf 3Y | -75.28% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - 0.00% | Gross Margin | -1025.61% | Volatility | 7.08% 6.88% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 154.32 | EPS Y/Y TTM | 33.40% | Oper. Margin | -4824.94% | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | Mar 22, 2018 | Quick Ratio | 3.05 | Sales Y/Y TTM | 33.33% | Profit Margin | -4613.11% | RSI (14) | 43.03 | Recom | 2.30 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.05 | EPS Q/Q | 41.46% | SMA20 | -8.92% | Beta | 2.25 | Target Price | 7.50 |
| Payout | 0.00% | Debt/Eq | 2.83 | Sales Q/Q | 0.00% | SMA50 | -4.38% | Rel Volume | 1.42 | Prev Close | 3.14 |
| Employees | 146 | LT Debt/Eq | 0.89 | Earnings | Nov 06 | SMA200 | -11.50% | Avg Volume | 3.28M | Price | 3.12 |
| IPO Date | Oct 20, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.70% -48.74% | Net Debt/EBITDA | -0.36 | Volume | 4,672,467 | Change | -0.64% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-25-26 | Reiterated | Chardan Capital | Buy | $7.00 |
| Jun-29-26 | Reiterated | New Street | $8.00 | |
| Jun-29-26 | Upgrade | HC Wainwright & Co. | Neutral → Buy | |
| Jun-22-26 | Reiterated | Goldman Sachs | $6.00 | |
| May-27-25 | Downgrade | Citigroup | Buy → Neutral | |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral | |
| May-20-25 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy | |
| May-07-24 | Reiterated | Jefferies | ||
| Apr-02-24 | Initiated | Wedbush | Buy | $12 |
Latest News· Times ET
Sep-17-26
Sep-16-26
Sep-16-2602:01PM
Sep-10-26
Sep-03-26
Sep-02-26
Sep-02-2612:09AM
Aug-19-26
Aug-19-2606:08AM
Aug-15-26
Aug-11-26
Aug-06-26
04:01AM
Jul-30-26
Jul-30-2607:06AM
Jul-23-26
Jul-23-2612:15PM
12:05PM
Jul-20-26
Jul-20-2611:16PM
Jul-09-26
Jul-09-2606:22AM
Company
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4 | 5 | 3 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 46 | 7 | 0 | — | — | — | — | — | |
| Gross Profit | -42 | -3 | 3 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 54 | 52 | 50 | — | — | — | — | — | |
| Research and Development | 146 | 161 | 155 | — | — | — | — | — | |
| Other Operating Expense | -46 | -7 | 0 | — | — | — | — | — | |
| Operating Income | -197 | -208 | -202 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 7 | 7 | — | — | — | — | — | |
| Net Income Before Taxes | -188 | -201 | -196 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -188 | -201 | -196 | — | — | — | — | — | |
| Net Income From Continuing Operations | -188 | -201 | -196 | — | — | — | — | — | |
| Net Income | -188 | -201 | -196 | — | — | — | — | — | |
| EPS (Recurring) | -1.10 | -1.35 | -1.65 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.10 | -1.35 | -1.65 | — | — | — | — | — | |
| EPS (Diluted) | -1.10 | -1.35 | -1.65 | — | — | — | — | — | |
| EBITDA | -180 | -196 | -190 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 138.06 | 103.41 | 115.83 | — | — | — | — | — | |
| Gross Margin | -1,050.00 | -60.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -4,925.00 | -4,160.00 | -6,733.33 | — | — | — | — | — | |
| Net Margin | -4,700.00 | -4,020.00 | -6,533.33 | — | — | — | — | — | |
| Shares Outstanding | 177 | 149 | 119 | — | — | — | — | — | |
| Market Capitalization | 552 | 517 | 347 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| GV 2021 GP, L.L.C. | 10% Owner | Aug 01 '25 | Buy | 3.30 | 1,500,000 | 4,950,000 | 3,262,440 | Aug 05 |
| ARCH Venture Partners X, LLC | 10% Owner | Aug 01 '25 | Buy | 3.30 | 3,030,300 | 9,999,990 | 6,230,300 | Aug 01 |
| NELSEN ROBERT | director, 10 percent owner: | Aug 01 '25 | Buy | 3.30 | 3,030,300 | 9,999,990 | 6,230,300 | Aug 01 |
| ARCH Venture Partners XII, LLC | 10% Owner | Aug 01 '25 | Buy | 3.30 | 3,030,300 | 9,999,990 | 6,230,300 | Aug 01 |
| Liu David R. | 10% Owner | Jun 30 '25 | Buy | 2.52 | 21,000 | 52,830 | 20,240,945 | Jul 01 |
| Liu David R. | 10% Owner | Jun 23 '25 | Buy | 2.16 | 21,000 | 45,402 | 20,219,945 | Jun 23 |
| Liu David R. | 10% Owner | Jun 16 '25 | Buy | 1.49 | 21,000 | 31,196 | 20,198,945 | Jun 16 |
| Liu David R. | 10% Owner | Jun 11 '25 | Buy | 1.60 | 21,000 | 33,590 | 20,177,945 | Jun 12 |
| LEE ANN L. | Chief Technical Officer | May 21 '25 | Buy | 1.13 | 100,000 | 113,000 | 100,000 | May 22 |
| Reine Allan | Chief Executive Officer | May 21 '25 | Buy | 1.18 | 125,000 | 147,150 | 125,000 | May 22 |
| Brudnick Richard | Chief Business Officer | May 20 '25 | Buy | 1.19 | 20,000 | 23,790 | 20,000 | May 22 |
| NELSEN ROBERT | director, 10 percent owner: | Feb 15 '24 | Buy | 6.25 | 3,200,000 | 20,000,000 | 3,200,000 | Feb 20 |
| ARCH Venture Partners XII, LLC | 10% Owner | Feb 15 '24 | Buy | 6.25 | 3,200,000 | 20,000,000 | 3,200,000 | Feb 20 |
| ARCH Venture Partners X, LLC | 10% Owner | Feb 15 '24 | Buy | 6.25 | 3,200,000 | 20,000,000 | 3,200,000 | Feb 20 |
| GV 2019 GP, L.L.C. | 10% Owner | Jun 21 '23 | Sale | 14.97 | 19,003 | 284,496 | 0 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.